I was participating in a Drumming Clinical Study, which I really enjoyed. And I was so disappointed that I was unable to ...
Broad endorsement for insurance-covered blood-based CRC screening (92%) suggests payer policy could materially influence ...
In this segment, Dr. Gregory Vidal discusses how common metastatic breast cancer is and explains how it may develop over time ...
Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...
Earlier-line bispecific therapy leverages lower disease refractoriness to drive deeper, more durable responses than typically seen in heavily pretreated settings. Combination regimens in earlier ...
Success in cancer care increasingly includes survivorship outcomes, emphasizing durable function and symptom control for patients cured and those with prolonged metastatic disease. Variable survival ...
Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...
Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and immunoediting compared with single-pathway CAR-T constructs. Complete tumor ...
In this segment, Dr. Gregory Vidal explains why it is essential for patients to understand their hormone receptor status and HER2 status when diagnosed with ER-positive, HER2-negative metastatic ...
A foundational guide for stage 2 prostate cancer clarifies staging implications, localized-disease management, and trade-offs among surgery, radiation, and quality-of-life outcomes to support informed ...
Epigenetic therapies are offering a more targeted way to treat some lymphomas by changing how genes are turned on or off ...
For many, a stage 4 breast cancer diagnosis can feels scary, but Casey Liening is rewriting that narrative. After a two-year ...